ArticleExploration of targeted anti-tumor therapy2025

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.

Ilya Tsimafeyeu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.